ArticleCase reports in oncology
Exceptional Response to Lenvatinib plus Pembrolizumab after Pembrolizumab Failure in MLH1-Methylated Deficient Mismatch Repair/Microsatellite Instability-High Endometrial Cancer: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endometrial cancer (EC) with deficient mismatch repair (dMMR) is a promising target for immune checkpoint inhibitor therapy. However, dMMR tumors are heterogeneous, and those with MLH1 promoter methylation respond less favorably to pembrolizumab monotherapy than Lynch syndrome-associated cases. Evidence for optimal treatment strategies in pembrolizumab-refractory dMMR tumors remains limited. Case Presentation: We report a woman in her 50s with recurrent endometrial carcinoma who was initially treated with surgery for stage IA, grade 1 endometrioid carcinoma. After recurrence with peritoneal dissemination and liver metastases, she received paclitaxel plus carboplatin with temporary response, followed by pembrolizumab monotherapy after detection of MSI-high status. However, disease progression occurred after two cycles. Immunohistochemistry (IHC) revealed loss of MLH1 and PMS2 expression, and EPM2AIP1 IHC suggested MLH1 promoter methylation. Given her preserved performance status, lenvatinib plus pembrolizumab (LP) therapy was initiated. Tumor markers, including CA125, decreased rapidly. Radiological assessments demonstrated marked shrinkage of peritoneal and liver metastases, with a durable response lasting at least 6 months. Adverse events, including stomatitis, hand-foot syndrome, arthritis, hypothyroidism, anorexia, fatigue, and fever, were manageable with supportive care and dose modification. Conclusion: This case illustrates that LP therapy can achieve a favorable response in dMMR EC with MLH1 promoter methylation after pembrolizumab failure. Further studies are warranted to clarify the biology of methylated dMMR tumors, establish individualized treatment strategies, and develop practical diagnostic systems to identify MLH1 promoter methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.